Soru

Zorluk: OrtaHematology and Oncology

A 4242-year-old woman is brought to the emergency department by her husband due to progressive confusion, lethargy, and a low-grade fever over the past 2424 hours. She has no significant past medical history. Her temperature is 37.8∘C37.8^\circ\text{C} (100.0∘F100.0^\circ\text{F}), blood pressure is 142/88142/88 mmHg, and pulse is 105105/min. Physical examination reveals petechiae on her lower extremities and scleral icterus. Neurologic examination shows a lethargic patient who is oriented only to person.

Laboratory studies show:
TestResult
Hemoglobin8.28.2 g/dL
Platelets22,00022,000/mm3^3
Leukocytes8,5008,500/mm3^3
Creatinine1.81.8 mg/dL
Total bilirubin3.23.2 mg/dL
Indirect bilirubin2.82.8 mg/dL
Lactate dehydrogenase850850 U/L

Arrange the following steps in the most appropriate chronological order for the management of this patient.

  1. 1Perform a peripheral blood smear to identify schistocytes
  2. 2Obtain a baseline blood sample for ADAMTS13 activity
  3. 3Initiate emergent therapeutic plasma exchange (PEX)
  4. 4Monitor platelet count and lactate dehydrogenase (LDH) daily to assess treatment response

Cevap

The correct sequence is: 1) Perform a peripheral blood smear to identify schistocytes, 2) Obtain a baseline blood sample for ADAMTS13 activity, 3) Initiate emergent therapeutic plasma exchange (PEX), and 4) Monitor platelet count and lactate dehydrogenase (LDH) daily to assess treatment response.
The patient's presentation of thrombocytopenia, hemolytic anemia, renal dysfunction, neurologic changes, and fever is highly suggestive of Thrombotic Thrombocytopenic Purpura (TTP). The first step is to confirm microangiopathic hemolytic anemia (MAHA) via a peripheral blood smear showing schistocytes. Once MAHA and thrombocytopenia are confirmed without another obvious cause, a presumptive diagnosis of TTP is made. Before administering any plasma, a blood sample for ADAMTS13 activity must be drawn, as donor plasma will alter baseline levels. Following this, therapeutic plasma exchange (PEX) must be initiated emergently. It is the primary life-saving treatment and should not be delayed while awaiting ADAMTS13 results. Finally, the patient's response to PEX and adjunctive immunosuppression is monitored daily by following the platelet count and LDH levels.

Adım Adım Çözüm

1
Identify the clinical syndrome
Suspected Thrombotic Thrombocytopenic Purpura (TTP)
The patient presents with the classic pentad: fever, neurologic changes, thrombocytopenia, hemolytic anemia, and renal dysfunction.
2
Select the initial diagnostic test
Peripheral blood smear
Visualizing schistocytes confirms microangiopathic hemolytic anemia (MAHA), establishing the presumptive diagnosis of TTP.
3
Identify the necessary pre-treatment laboratory draw
ADAMTS13 activity and inhibitor assay
Blood must be drawn before giving donor plasma to accurately measure the patient's baseline enzyme activity.
4
Select the emergent definitive therapy
Therapeutic plasma exchange (PEX)
PEX removes autoantibodies and replenishes ADAMTS13; it must be started immediately without waiting for confirmatory assay results.
5
Determine the follow-up monitoring strategy
Daily monitoring of platelets and LDH
These markers indicate the resolution of microthrombi and hemolysis, guiding the duration of PEX.

Anahtar Kavram

Sequential management of suspected Thrombotic Thrombocytopenic Purpura (TTP)
Tahmini Süre:1m 30s
Bu soruyu puanla